Hepatic interferon receptor mRNA expression: Clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection

Antiviral Therapy

Volumn 11, Issue 1, 2006, Pages 17-23

  Lee, Chuan Mo ^a   Kee, Kwong Ming ^a   Hung, Chao Hung ^a   Eng, Hock Liew ^a   Chang, Chien Hwa ^a   Huang, Chao Min ^a   Wang, Jing Houng ^a   Hu, Tsung Hui ^a   Lu, Sheng Nan ^a   Changchien, Chi Sin ^a   Chen, Wei Jen ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON RECEPTOR; MESSENGER RNA; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA TRANSCRIPTION;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER; MALE; MIDDLE AGED; RECEPTORS, INTERFERON; RIBAVIRIN; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 33644545744     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15:5-14.
2. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-832.
3. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671-675.
4. Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999; 86:1143-1150.
5. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-1432.
6. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492.
7. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37:600-609.
8. Hung CH, Lee CM, Lu SN, et al. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat 2003; 10:87-94.
9. Kao JH, Chen PJ, Lai MY, et al. Genotypes of hepatitis C virus in Taiwan and the progression of liver disease. J Clin Gastroenterol 1995; 21:233-237.
10. Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study group. Ann Intern Med 1996; 125:634-639.
11. Levy DE, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 2001; 12:143-156.
12. Domanski P, Witte M, Kellum M, et al. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J Biol Chem 1995; 270:21606-21611.
13. Colamonici OR, Domanski P. Identification of a novel subunit of the type I interferon receptor localized to human chromosome 21. J Biol Chem 1993; 268:10895-108999.
14. Domanski P, Colamonici OR. The type-I interferon receptor. The long and short of it. Cytokine Growth Factor Rev 1996; 7:143-151.
15. Muller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264:1918-1921.
16. Muller M, Ibelgaufts H, Kerr IM. Interferon response pathways-a paradigm for cytokine signaling? J Viral Hepat 1994; 1:87-103.
17. Ishimura N, Fukuda R, Fukumoto S. Relationship between the intrahepatic expression of interferon-alpha receptor mRNA and the histological progress of hepatitis C virus-associated chronic liver diseases. J Gastroenterol Hepatol 1996; 11:712-717.
18. Fukuda R, Ishimura N, Ishihara S, et al. Expression of interferon-alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: relation to effectiveness of interferon therapy. J Gastroenterol 1996; 31:806-811.
19. Fukuda R, Ishimura N, Kushiyama Y, et al. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol 1997; 26:455-461.
20. Yatsuhashi H, Yamasaki K, Aritomi T, et al. Quantitative analysis of interferon alpha/beta receptor mRNA in the liver of patients with chronic hepatitis C: correlation with serum hepatitis C virus-RNA levels and response to treatment with interferon. J Gastroenterol Hepatol 1997; 12:460-167.
21. Morita K, Tanaka K, Saito S, et al. Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection. J Clin Gastroenterol 1998; 26:135-140.
22. Yatsuhashi H, Fujino T, Matsumoto T, et al. Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C. J Hepatol 1999; 30:995-1003.
23. Morita K, Tanaka K, Saito S, et al. Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C. J Med Virol 1999; 58:359-365.
24. Mathai J, Shimoda K, Banner BF, et al. IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy. J Interferon Cytokine Res 1999; 19:1011-1018.
25. Yin JL, Shackel NA, Zekry A, et al. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I. Immunol Cell Biol 2001; 79:213-221.
26. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-1520.
27. Fujiwara D, Hino K, Yamaguchi Y, et al. Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. J Viral Hepat 2004; 11:136-140.
28. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35:1002-1009.
29. Sintchak MD, Nimmesgern E. The structure of inosine 5′- monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000; 47:163-184.
30. Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001; 276:46094-46098.
31. Lanford RE, Chavez D, Guerra B, et al. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol 2001; 75:8074-8081.
32. Kalvakolanu DV. Alternate interferon signaling pathways. Pharmacol Ther 2003; 100:1-29.
33. Chung J, Uchida E, Grammer TC, Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997; 17:6508-6516.
34. Stancato LF, Sakatsume M, David M, et al. Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway. Mol Cell Biol 1997; 17:3833-3840.
35. Miyajima I, Sata M, Gondo K, Suzuki H, Tanikawa K. Interferon accumulation in cirrhotic rat liver. J Viral Hepat 1996; 3:23-27.